SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GhostwareOS (GHOST) is the Full-Stack Privacy Layer of Solana — a next-generation AI-driven infrastructure for encrypted communication, anonymous identity management, and untraceable transactions. By combining advanced zero-knowledge protocols with autonomous AI routing, GhostwareOS allows users and developers to operate invisibly across Web3. It powers decentralized apps that demand true digital anonymity, scalable privacy, and zero metadata leakage — restoring control to users in an overexposed internet age.

Ghost

GHOST is generating significant buzz as the privacy layer on Solana, holding remarkably strong amidst broader market volatility and trending high across crypto discussions. The community is actively touting its low market cap, promising utility with integrations like Zebec Network, and an anticipated revenue-sharing model.

Fartcoin is a meme-driven cryptocurrency where users can submit their best fart jokes or memes to earn initial tokens. Each transaction triggers a hilarious 'Gas Fee' effect, complete with a digital fart sound for maximum comedic impact.

Fartcoin

Fartcoin is generating significant buzz and dividing the crypto community following its recent listings on major exchanges, with supporters anticipating substantial gains while skeptics view it as a highly volatile meme coin prone to pump-and-dump cycles.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU CRYPTO is trending due to its exceptionally dedicated community actively building a "permissionless brand" through consistent real-world product launches. This grassroots effort generates strong bullish conviction and frequently places KENDU at the top of crypto trending lists, even during market volatility.

Aster is a next-generation decentralized perpetual exchange that combines non-custodial trading with advanced features like hidden orders and multi-chain support. The platform emerged from the merger of Astherus and APX Finance in late 2024, with APX token holders able to migrate their holdings to ASTER.  Aster addresses the gap between centralized and decentralized exchanges by enabling traders to maintain full control of their assets while accessing deep liquidity and CEX-grade trading tools. The platform supports trading of both cryptocurrency perpetuals and U.S. stocks with up to 100x leverage, all settled on-chain in crypto without requiring traditional financial infrastructure.  The platform offers two distinct trading modes to accommodate different user needs. Simple Mode provides one-click, MEV-resistant trading with up to 1001x leverage for beginners, while Pro Mode delivers a full order book with advanced features like automated grid trading and hidden orders that remain invisible until execution.   Aster operates across BNB Chain, Ethereum, Solana, and Arbitrum without requiring bridging, with liquidity pooled across markets to support large trades with minimal slippage. A distinctive feature allows users to deposit yield-generating assets like asBNB or USDF as collateral, earning passive returns while trading, maximizing capital efficiency compared to platforms where collateral sits idle.  Aster received backing from YZi Labs (formerly Binance Labs), which holds a minority stake through a private fund managing over $10 billion on behalf of early Binance executives. Changpeng Zhao, founder of Binance, serves in an advisory role and has personally invested over $2.5 million worth of ASTER tokens.   The ASTER token serves multiple functions including governance rights, staking rewards through liquidity provision, and earning incentives through the platform's points program for traders and liquidity providers.

ASTERION

ASTER is a hot topic as a decentralized exchange (DEX) token, with community discussion centered on a recent significant token burn and perceived strong backing from CZ, fueling both bullish predictions for its potential to rival platforms like Hyperliquid and sharp skepticism about its underlying value and potential for manipulation.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

WEEDCOIN is surging with community optimism ahead of the 4/20 cultural event, driven by its 'like Bitcoin but way higher' mantra and a vision for global cannabis legalization, fostering a culture of patience and long-term engagement.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending after announcing it will stop offering its compounded weight-loss pill due to escalating federal regulatory scrutiny, fueling a polarized community debate between bears predicting a major downfall and bulls anticipating a short squeeze and long-term rebound due to reduced risk and strong underlying business.

Kelly Services, Inc. engages in the provision of talent solutions. It operates through the following segments: Professional and Industrial, Science, Engineering, and Technology, Education, Outsourcing and Consulting, and International. The Professional and Industrial segment includes the provision of administrative, accounting and finance, light industrial, contact center staffing, and other workforce solutions. The Science, Engineering, and Technology segment focuses on staffing, outcome-based, permanent placement services, clinical research, and telecommunications. The Education segment involves offering education and therapy services talent through staffing, permanent placement, and executive search services to Pre-K-12 school districts and organizations. The Outsourcing and Consulting segment consists of global talent supply chain and workforce solutions, including Managed Service Provider (MSP), Recruitment Process Outsourcing (RPO), Payroll Process Outsourcing (PPO), and executive coaching programs. The company was founded by William Russell Kelly on October 7, 1946 and is headquartered in Troy, MI.

Kelly Services, Inc. - Ordinary Shares - Class B

KELYB is trending due to Hunt Equity's acquisition of a 92.2% controlling stake, which has severely reduced the Class B share float to a few hundred thousand shares, sparking widespread community speculation about a massive short squeeze. Traders are actively discussing the extremely tight float and anticipating significant price volatility, particularly with upcoming earnings as a potential catalyst.

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit (INTU) is experiencing a significant sell-off driven by widespread market fears that AI advancements will disrupt its core tax and accounting software, intensified by recent analyst downgrades and cautious guidance, despite management's efforts to integrate AI and community arguments that the stock is now oversold.

Hawaiian Electric Industries, Inc. is a holding company, which engages in electric utility and non-regulated renewable and sustainable infrastructure businesses. The company was founded by C. Dudley Pratt Jr. in 1981 and is headquartered in Honolulu, HI.

Hawaiian Electric Industries, Inc.

Hawaiian Electric Industries is trending as major institutional investors significantly increase their holdings and legislative efforts progress to bolster its financial stability after wildfire settlements, fueling community anticipation for the utility's long-term recovery and potential dividend reinstatement.

Kinder Morgan, Inc. engages in providing pipeline transportation of natural gas services. It operates through the following business segments: Natural Gas Pipelines, Products Pipelines, Terminals, and CO2. The Natural Gas Pipelines segment operates major interstate and intrastate natural gas pipelines and storage systems. The Products Pipelines segment is involved in the operation of refined petroleum products, crude oil, and condensate pipelines. The Terminals segment includes the operation of liquids and bulk terminal facilities that store and handle various commodities. The CO2 segment produces, transports, and markets to oil fields that use CO2 as a flooding medium to increase recovery and production of crude oil from mature oil fields. The company was founded by Richard D. Kinder and William V. Morgan in February 1997 and is headquartered in Houston, TX.

Kinder Morgan Inc - Ordinary Shares - Class P

Kinder Morgan is drawing significant attention following its Q4 earnings, which showed a revenue beat and strong FY25 guidance, boosted by record natural gas pipeline performance and a massive project backlog aimed at surging LNG and AI data center demand. The community is actively debating KMI's long-term growth and reliable dividend against recent upward momentum, with many viewing it as a resilient energy infrastructure play.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVistas Board of Directors granted six newly-hired employees inducement options to purchase an...

Wall Street Analysts Believe KalVista Pharmaceuticals (KALV) Could Rally 116.4%: Here's is How to Trade

The consensus price target hints at an 116.4% upside potential for KalVista Pharmaceuticals (KALV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Emerald Mutual Fund Advisers Trust Grows Stake in KalVista Pharmaceuticals, Inc. $KALV

Emerald Mutual Fund Advisers Trust boosted its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 19.4% during the 3rd quarter, according to its most recent disclosure...

Emerald Advisers LLC Grows Position in KalVista Pharmaceuticals, Inc. $KALV

Emerald Advisers LLC raised its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 30.2% during the third quarter, according to its most recent filing with the SEC...

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of "Moderate Buy" from Brokerages

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) has been given an average rating of "Moderate Buy" by the nine research firms that are presently covering the stock, MarketBeat Ratings...

Does KalVista Pharmaceuticals (KALV) Have the Potential to Rally 117.98% as Wall Street Analysts Expect?

The mean of analysts' price targets for KalVista Pharmaceuticals (KALV) points to an 118% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Down 7.2% - Time to Sell?

KalVista Pharmaceuticals (NASDAQ:KALV) Shares Down 7.2% - What's Next...

<ul class="summary-bullets"><li>KalVista launched Ekterly in the U.S. in July for the treatment of acute attacks of hereditary angioedema in adults and children aged 12 years and older.</li><li>Through the full year 2025, the company recorded global Ekterly revenue of $49 million.</li><li>Kalvista now plans to file a new drug application with the FDA for the drug in pediatric HAE patients aged 2 to 11 years in the third quarter of 2026.</li></ul>Shares of KalVista Pharmaceuticals, Inc. (KALV) jumped 14% after hours on Thursday after the company said that it recorded about $35 million in revenue from its one and only approved drug Ekterly in the fourth quarter, merely months after launch.KalVista <a href="https://stocktwits.com/news-articles/markets/equity/kalvista-gets-fda-approval-for-drug-in-treating-swelling-disorder/chFtmFCR57B">launched</a> Ekterly in the U.S. in July for the treatment of acute attacks of hereditary angioedema in adults and children aged 12 years and older. The company said that in the three months through the end of December, prescription refills surpassed initial prescriptions as the primary driver of revenue.Hereditary angioedema (HAE) is a rare genetic disease caused by deficiency or dysfunction of a protein called the C1 esterase inhibitor, where patients experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected.<h2 class="st-heading-2">Ekterly’s Edge</h2>Ekterly is the first and only oral on-demand treatment for HAE, KalVista said, setting it apart from other on-demand HAE treatment options approved in the U.S., which require intravenous or subcutaneous administration.Through the full year 2025, the company recorded global Ekterly revenue of $49 million. The drug is now approved in seven global markets including the U.S., United Kingdom, European Union, Switzerland, Australia, Singapore and Japan.“Fundamental demand has remained strong, with some effects from seasonal variability, and we are encouraged by the continued high level of interest in switching to EKTERLY,” CEO Ben Palleiko said. “Internationally, we are seeing strong uptake in Germany, with early prescribing behaviors mirroring the positive trends we observed in the US, and we expect to expand into other major markets during 2026.”Kalvista now plans to file a new drug application with the FDA for the drug in pediatric HAE patients aged 2 to 11 years in the third quarter of 2026. The company envisions launching the drug for the younger population in the U.S. in 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around KalVista jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user applauded the numbers as an “incredible start to Ekterly sales.” “This has a squeeze written all over it,” the user added.<stembedurl>https://www.stocktwits.com/pblegend66/message/641279255</stembedurl>Another user highlighted the drug’s potential and noted that the company could make as much as $340 million in revenue from the drug.<stembedurl>https://www.stocktwits.com/Biocontrol/message/641276040</stembedurl><a href="https://stocktwits.com/symbol/KALV">KALV stock</a> has gained 92% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/general-motors-incurs-7.1-billion-in-charges-in-q4/cmUbl4LR451">General Motors Incurs $7.1B In Charges In Q4 Pertaining To Slowing EV Demand, China Business Restructuring</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart

Ekterly is the first and only oral on-demand treatment for HAE, KalVista said, setting it apart from other on-demand HAE treatment options approved in the U.S.

Equity

Ekterly is the first and only oral on-demand treatment for HAE, KalVista said, setting it apart from other on-demand HAE treatment options approved in the U.S.


KalVista Pharmaceuticals Provides Update on Strong EKTERLY Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided its preliminary fourth quarter and full year ended December 31, 2025 unaudited global net product revenue results and other operational...

KalVista Pharmaceuticals (NASDAQ:KALV) Sees Unusually-High Trading Volume - Still a Buy?

KalVista Pharmaceuticals (NASDAQ:KALV) Sees Strong Trading Volume - What's Next...

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

KalVista Pharmaceuticals Inc

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

Current Price	$15.35
Prev Close	$14.40
Open	$14.78
Dividend Yield	0.00%
50-Day Moving Average	$15.53
Beta	0.96
Avg. Volume	1.3M
PE Ratio	-3.73

52-Week High	$19.00
52-Week Low	$8.84
Market Capitalization	$753.14M
EPS (Annual)	-$3.69
Price to Book	44.30
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

KALV
KalVista Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KALV News

KALVKalVista Pharmaceuticals Inc